Your browser is no longer supported. Please, upgrade your browser.
Settings
BOLD Audentes Therapeutics, Inc. daily Stock Chart
BOLD [NASD]
Audentes Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.65 Insider Own1.10% Shs Outstand35.49M Perf Week8.77%
Market Cap1.47B Forward P/E- EPS next Y-3.45 Insider Trans-67.38% Shs Float35.49M Perf Month-3.22%
Income-78.10M PEG- EPS next Q-0.78 Inst Own- Short Float6.22% Perf Quarter7.64%
Sales- P/S- EPS this Y52.40% Inst Trans0.39% Short Ratio5.25 Perf Half Y9.43%
Book/sh10.19 P/B4.07 EPS next Y-8.50% ROA-41.50% Target Price41.27 Perf Year98.61%
Cash/sh9.19 P/C4.51 EPS next 5Y8.80% ROE-46.20% 52W Range15.74 - 46.18 Perf YTD32.58%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-10.29% Beta-
Dividend %- Quick Ratio20.40 Sales past 5Y- Gross Margin- 52W Low163.21% ATR1.72
Employees152 Current Ratio20.40 Sales Q/Q- Oper. Margin- RSI (14)62.24 Volatility3.97% 4.41%
OptionableYes Debt/Eq0.00 EPS Q/Q11.20% Profit Margin- Rel Volume0.72 Prev Close40.65
ShortableYes LT Debt/Eq0.00 EarningsAug 09 AMC Payout- Avg Volume420.42K Price41.43
Recom2.00 SMA205.38% SMA507.89% SMA20024.67% Volume304,075 Change1.92%
Jun-26-18Initiated Chardan Capital Markets Neutral $35
Feb-13-18Initiated Mizuho Neutral $26
Dec-20-17Initiated H.C. Wainwright Buy $37
Oct-17-17Initiated William Blair Outperform
Oct-16-17Downgrade Evercore ISI Outperform → In-line
Oct-12-17Initiated Raymond James Mkt Perform
Aug-17-17Initiated Evercore ISI Outperform $23
May-01-17Initiated Leerink Partners Outperform
Jul-20-18 09:30AM  Is Audentes Therapeutics (BOLD) Stock Outpacing Its Medical Peers This Year? Zacks
Jun-26-18 07:10AM  Free Technical Reports on Array BioPharma and Three Additional Biotech Equities ACCESSWIRE
Jun-05-18 08:00AM  Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular Myopathy PR Newswire
May-31-18 08:25AM  Market Trends Toward New Normal in Audentes Therapeutics, Aqua Metals, BT Group, Mid-America Apartment Communities, MDC Partners, and Hexcel Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-29-18 08:00AM  Audentes Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference PR Newswire
May-28-18 08:02AM  Edited Transcript of BOLD earnings conference call or presentation 9-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-18-18 07:05AM  Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space ACCESSWIRE -7.61%
May-16-18 11:30AM  Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy PR Newswire
May-10-18 07:25AM  Wired News - Ascendis Pharma Dosed First Subjects in First-in-Human Phase-1 Trial of TransCon CNP ACCESSWIRE -9.05%
May-09-18 04:43PM  Audentes Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
11:23AM  What Should We Expect From Audentes Therapeutics Incs (NASDAQ:BOLD) Earnings In The Next Couple Of Years? Simply Wall St.
08:00AM  Audentes Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference 2018 PR Newswire
May-08-18 08:00AM  Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating Officer PR Newswire
May-02-18 08:00AM  Audentes Therapeutics to Release First Quarter 2018 Financial Results and Provide Corporate Update on Wednesday, May 9, 2018 PR Newswire
Apr-30-18 01:14PM  Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy PR Newswire
Apr-05-18 08:30AM  New Research: Key Drivers of Growth for Aqua Metals, Audentes Therapeutics, Gaming and Leisure Properties, Mammoth Energy Services, Inc., ONE Gas, and Mettler-Toledo International Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-30-18 01:26PM  Edited Transcript of BOLD earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-08-18 04:25PM  Audentes Therapeutics reports 4Q loss Associated Press
04:01PM  Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate Update PR Newswire
01:00PM  Audentes Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-07-18 08:46AM  Is a Surprise Coming for Audentes Therapeutics (BOLD) This Earnings Season? Zacks
07:35AM  New Research: Key Drivers of Growth for Entergy, CarMax, Verifone, Audentes Therapeutics, EZCORP, and Cabot Microelectronics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-06-18 08:00AM  Audentes Therapeutics to Present at the Cowen 38th Annual Health Care Conference PR Newswire
Mar-01-18 08:00AM  Audentes Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update on Thursday, March 8, 2018 PR Newswire
Feb-28-18 08:00AM  Audentes Therapeutics Joins Global Organizations In Recognizing Rare Disease Day® 2018 PR Newswire
Feb-12-18 08:00AM  Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome PR Newswire
Feb-08-18 08:00AM  Audentes Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference PR Newswire -7.92%
Feb-06-18 07:30PM  Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program PR Newswire
Jan-29-18 04:01PM  Audentes Therapeutics Announces the Closing of its Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire
Jan-24-18 07:43PM  Audentes Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire
Jan-23-18 04:01PM  Audentes Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Jan-05-18 08:56AM  Audentes Therapeutics (BOLD) Jumps: Stock Rises 14.9% Zacks -10.25%
Jan-04-18 04:38PM  Biotech Stock Rockets To Record On Gene Therapy Trial In Children Investor's Business Daily +14.86%
12:30PM  Audentes Therapeutics Pulls Off Positive Interim Results 24/7 Wall St.
07:00AM  Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy PR Newswire
Jan-03-18 08:00AM  Audentes Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-13-17 08:00AM  Audentes Therapeutics Appoints Mark A. Goldberg, M.D. to its Board of Directors PR Newswire
Dec-07-17 08:25AM  Edited Transcript of BOLD earnings conference call or presentation 14-Nov-17 9:30pm GMT Thomson Reuters StreetEvents +5.32%
Nov-21-17 08:00AM  Audentes Therapeutics Announces Publication of Data from RECENSUS, a Retrospective Medical Record Review of Patients With X-Linked Myotubular Myopathy PR Newswire
Nov-16-17 08:00AM  Audentes Therapeutics to Present at Upcoming Investor Conferences PR Newswire +5.79%
05:14AM  Audentes Therapeutics reports 3Q loss Associated Press
Nov-14-17 04:01PM  Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
12:00PM  Audentes Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-07-17 08:00AM  Audentes Therapeutics to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 14, 2017 PR Newswire
Oct-13-17 12:09PM  How Spark's Gene Therapy Win Could Also Be A Boon For These Biotechs Investor's Business Daily
Sep-27-17 04:07PM  This Biotech Makes Bold Move On Potential For Speedier Drug OK Investor's Business Daily
08:00AM  Audentes Therapeutics Announces Rare Pediatric Disease and Fast Track Designations for AT132 for the Treatment of X-Linked Myotubular Myopathy PR Newswire
Sep-21-17 08:00AM  Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy PR Newswire
Sep-19-17 08:00AM  Audentes Therapeutics to Present at Upcoming Investor Conferences PR Newswire
Sep-05-17 07:40AM  Featured Company News Acorda Therapeutics Adopts Poison Pill ACCESSWIRE
Aug-10-17 11:54PM  Audentes Therapeutics reports 2Q loss Associated Press -15.34%
08:00AM  Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
Jul-18-17 08:00AM  Audentes Therapeutics Announces Appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe PR Newswire
Jun-28-17 08:00AM  Audentes Therapeutics Announces Participation in Upcoming Investor Conferences PR Newswire
Jun-13-17 08:00AM  Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors PR Newswire +7.01%
May-19-17 08:31AM  Why Audentes Therapeutics (BOLD) Could Be Positioned for a Surge Zacks
May-11-17 08:10AM  Audentes Therapeutics reports 1Q loss Associated Press
08:00AM  Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
May-10-17 08:00AM  Audentes Therapeutics to Present At Upcoming Investor Conferences PR Newswire
May-08-17 08:00AM  Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer PR Newswire
May-03-17 08:00AM  Audentes Therapeutics Announces Presentation of Data at the American Society of Gene and Cell Therapy Annual Meeting PR Newswire
Apr-19-17 09:55AM  Audentes Therapeutics Gears Up for Secondary Offering 24/7 Wall St. -5.20%
Apr-18-17 06:44PM  Audentes Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire -6.87%
Apr-17-17 08:00AM  Audentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day PR Newswire
Apr-03-17 05:07PM  AUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT132 to Treat X-Linked Myotubular Myopathy PR Newswire
Mar-20-17 08:00AM  Audentes Therapeutics Announces Presentation Of Data From RECENSUS, A Medical Chart Review Of Patients With X-Linked Myotubular Myopathy (XLMTM) PR Newswire
Mar-16-17 01:04PM  AUDENTES THERAPEUTICS, INC. Financials
Mar-13-17 06:05AM  AUDENTES THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
Mar-09-17 08:12AM  Audentes Therapeutics reports 4Q loss Associated Press
08:06AM  AUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
08:00AM  Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update PR Newswire
Mar-07-17 08:02AM  AUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-01-17 08:00AM  Audentes Therapeutics Announces Commencement of LUSTRO, a Clinical Assessment and Phase 1/2 Run-in Study of Patients with Crigler-Najjar Syndrome PR Newswire
Feb-07-17 08:00AM  Audentes Therapeutics to Present at Upcoming Investor Conferences PR Newswire
Feb-01-17 08:00AM  Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome PR Newswire
Jan-09-17 08:00AM  Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance PR Newswire
Jan-04-17 08:00AM  Audentes Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-13-16 08:02AM  AUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
08:00AM  Audentes Therapeutics Appoints Julie Anne Smith to Board of Directors PR Newswire
Dec-08-16 03:07PM  How Hedge Funds Played the Audentes Therapeutics Inc (BOLD) IPO at Insider Monkey +5.76%
Nov-29-16 08:00AM  Audentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility PR Newswire
07:25AM  AUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Nov-21-16 08:00AM  Audentes Therapeutics to Attend Piper Jaffray 28th Annual Healthcare Conference PR Newswire
Nov-14-16 06:10AM  AUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
Nov-10-16 04:22PM  AUDENTES THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report +7.32%
08:00AM  Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update PR Newswire
Oct-20-16 05:25PM  Supersized IPO charges up S.F. med device maker's first day at bizjournals.com
Sep-28-16 07:02AM  AUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +9.69%
Sep-21-16 08:00AM  Audentes Therapeutics to Present at Upcoming Investor Conferences PR Newswire
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patterson Matthew RChief Executive OfficerJul 05Option Exercise0.7823,14718,05523,147Jul 05 06:34 PM
Patterson Matthew RChief Executive OfficerJul 05Sale40.0423,147926,8520Jul 05 06:34 PM
Patterson Matthew RChief Executive OfficerJul 03Option Exercise0.7826,90120,98326,901Jul 05 06:34 PM
Patterson Matthew RChief Executive OfficerJul 03Sale40.0526,9011,077,4600Jul 05 06:34 PM
Patterson Matthew RChief Executive OfficerJul 02Option Exercise0.7821,00016,38019,599Jul 05 06:34 PM
PRASAD SUYASHSenior VP & Chief Med OfficerJul 02Option Exercise0.7910,0007,9005,011Jul 05 06:35 PM
PRASAD SUYASHSenior VP & Chief Med OfficerJul 02Sale38.4110,000384,0670Jul 05 06:35 PM
Patterson Matthew RChief Executive OfficerJul 02Sale38.3621,000805,5240Jul 05 06:34 PM
NEWMAN MARYSVP, Regulatory AffairsJun 25Option Exercise2.198,54518,6738,245Jun 27 06:52 PM
NEWMAN MARYSVP, Regulatory AffairsJun 25Sale40.798,545348,5810Jun 27 06:52 PM
LANGE LOUIS GDirectorJun 25Sale40.8613,000531,1542,558Jun 27 06:51 PM
LANGE LOUIS GDirectorJun 25Sale40.4220,000808,344385,799Jun 27 06:51 PM
Nagler DavidSVP, HR & Corp. AffairsJun 20Option Exercise2.195,00010,9264,700Jun 22 07:11 PM
Nagler DavidSVP, HR & Corp. AffairsJun 20Sale45.295,000226,4610Jun 22 07:11 PM
Holles Natalie C.President and COOJun 01Option Exercise2.765,09014,07325,090Jun 04 04:48 PM
Patterson Matthew RPresident & CEOMay 21Option Exercise0.7820,30015,83413,600May 23 06:13 PM
Patterson Matthew RPresident & CEOMay 21Sale38.1520,300774,4980May 23 06:13 PM
Patterson Matthew RPresident & CEOApr 02Option Exercise0.78700546700Apr 04 09:01 PM
Patterson Matthew RPresident & CEOApr 02Sale30.0170021,0090Apr 04 09:01 PM
PRASAD SUYASHSenior VP & Chief Med OfficerMar 29Option Exercise0.797,8006,1627,800Mar 29 08:23 PM
PRASAD SUYASHSenior VP & Chief Med OfficerMar 27Option Exercise0.79300237300Mar 28 09:12 PM
PRASAD SUYASHSenior VP & Chief Med OfficerMar 26Option Exercise0.791,9001,5011,900Mar 28 09:12 PM
PRASAD SUYASHSenior VP & Chief Med OfficerMar 26Sale30.001,90057,0000Mar 28 09:12 PM
LANGE LOUIS GDirectorMar 26Sale28.6228,000801,4733,558Mar 28 09:11 PM
LANGE LOUIS GDirectorMar 26Sale29.2720,000585,464405,799Mar 28 09:11 PM
NEWMAN MARYSVP, Regulatory AffairsMar 15Option Exercise2.1910,00021,9005,524Apr 02 09:06 PM
NEWMAN MARYSVP, Regulatory AffairsMar 15Sale30.3610,000303,6270Apr 02 09:06 PM
ORBIMED ADVISORS LLC10% OwnerMar 12Sale34.9918,003629,8593,539,997Mar 12 06:16 PM
ORBIMED ADVISORS LLC10% OwnerMar 09Sale35.6380,0002,850,0103,558,000Mar 12 06:16 PM
ORBIMED ADVISORS LLC10% OwnerMar 08Sale34.0658,4281,990,0583,638,000Mar 12 06:16 PM
ORBIMED ADVISORS LLC10% OwnerMar 06Sale33.0311,372375,6173,696,428Mar 06 05:53 PM
ORBIMED ADVISORS LLC10% OwnerMar 05Sale36.062007,2123,707,800Mar 06 05:53 PM
ORBIMED ADVISORS LLC10% OwnerMar 02Sale35.17421,63814,827,7873,708,000Mar 06 05:53 PM
LANGE LOUIS GDirectorDec 22Sale30.883,00092,6334,558Dec 26 07:38 PM
LANGE LOUIS GDirectorDec 22Sale30.8815,000463,160425,799Dec 26 07:38 PM
PRASAD SUYASHSenior VP & Chief Med OfficerDec 01Option Exercise0.798,0006,3206,770Dec 05 04:00 PM
PRASAD SUYASHSenior VP & Chief Med OfficerDec 01Sale28.538,000228,2640Dec 05 04:00 PM
NEWMAN MARYSVP, Regulatory AffairsNov 16Option Exercise2.1910,00021,9005,740Nov 17 05:06 PM
NEWMAN MARYSVP, Regulatory AffairsNov 16Sale26.8410,000268,3750Nov 17 05:06 PM
Patterson Matthew RPresident & CEOOct 02Option Exercise0.7810,0007,80010,000Oct 04 08:25 PM
Patterson Matthew RPresident & CEOOct 02Sale27.9215,000418,853171,814Oct 04 08:25 PM
Patterson Matthew RPresident & CEOOct 02Sale27.9210,000279,2170Oct 04 08:25 PM
ORBIMED ADVISORS LLC10% OwnerSep 29Sale28.25672,00018,984,0004,129,638Sep 29 06:06 PM
LANGE LOUIS GDirectorSep 29Sale28.266,000169,5885,558Sep 29 05:47 PM
LANGE LOUIS GDirectorSep 29Sale28.465,000142,315440,799Sep 29 05:47 PM
Nagler DavidSVP, HR & Corp. AffairsSep 27Option Exercise2.193,7508,1953,750Sep 29 05:48 PM
Nagler DavidSVP, HR & Corp. AffairsSep 27Sale30.003,750112,5000Sep 29 05:48 PM
LANGE LOUIS GDirectorSep 25Sale28.353,00085,0557,558Sep 26 05:44 PM
LANGE LOUIS GDirectorSep 25Sale28.3115,000424,672445,799Sep 26 05:44 PM
Patterson Matthew RPresident & CEOSep 18Option Exercise0.788,4586,5978,458Sep 19 06:00 PM
Patterson Matthew RPresident & CEOSep 18Sale25.078,458212,0100Sep 19 06:00 PM
Nagler DavidSVP, HR & Corp. AffairsSep 15Option Exercise2.193,7508,1953,750Sep 19 05:59 PM
Patterson Matthew RPresident & CEOSep 15Option Exercise0.781,5421,2031,542Sep 19 06:00 PM
Patterson Matthew RPresident & CEOSep 15Sale25.001,54238,5510Sep 19 06:00 PM
Nagler DavidSVP, HR & Corp. AffairsSep 15Sale25.003,75093,7500Sep 19 05:59 PM
ORBIMED ADVISORS LLC10% OwnerSep 07Sale22.355,000111,7504,801,638Sep 11 02:16 PM
PRASAD SUYASHSenior VP & Chief Med OfficerSep 01Option Exercise0.798,0006,3208,000Sep 01 05:55 PM
PRASAD SUYASHSenior VP & Chief Med OfficerSep 01Sale21.448,000171,4810Sep 01 05:55 PM
NEWMAN MARYSVP, Regulatory AffairsAug 24Option Exercise2.1910,00021,90010,000Aug 25 04:17 PM
NEWMAN MARYSVP, Regulatory AffairsAug 24Sale20.0010,000200,0000Aug 25 04:17 PM